Yes, there are clinical trial opportunities available for Keytruda (pembrolizumab). Keytruda is an immunotherapy drug used to treat various types of cancer. Clinical trials are an essential part of the drug development process, allowing researchers to evaluate the safety and effectiveness of new treatments.
One source, Drug Patent Watch, provides information on the patent status of Keytruda, which indicates that the drug is still under patent protection [1]. This suggests that ongoing research and development may be taking place, including clinical trials.
The official Keytruda website also provides information on clinical trial results [2]. While this source does not explicitly mention ongoing clinical trials, it highlights the outcomes of completed trials, indicating that research is being conducted to evaluate the drug's efficacy and safety.
Additionally, the National Cancer Institute's website provides a database of clinical trials, including those involving pembrolizumab (Keytruda) [3]. This database allows individuals to search for clinical trials based on specific criteria, such as cancer type, location, and eligibility criteria.
Based on these sources, it can be inferred that there are ongoing clinical trial opportunities for Keytruda. However, it is important to note that the availability of clinical trials may vary depending on factors such as the specific type of cancer being studied, the location, and the stage of the drug's development. Therefore, individuals interested in participating in a clinical trial should consult with their healthcare provider and explore the resources provided by organizations such as the National Cancer Institute.
Sources:
[1] Drug Patent Watch: Keytruda Patent and Exclusivity Information. Retrieved from https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA
[2] Keytruda Official Website: Clinical Trial Results. Retrieved from https://www.keytruda.com/clinical-trial-results/
[3] National Cancer Institute: Pembrolizumab Clinical Trials. Retrieved from https://www.cancer.gov/research/participate/clinical-trials/intervention/pembrolizumab